ZHANG Research Team
Nano Biomedicine Lab

Introduction - NBM

   The research group has conducted research on the problems faced by accurate imaging diagnosis and efficient treatment of clinical cancer. Guided by the actual needs of clinical cancer, the group has proposed a new strategy for regulating the function of cell membrane proteins in vivo, has constructed a variety of nanomaterials precise delivery systems, explored the mechanism of nanoparticles in vivo, and realized the clinical translation application of frontier basic research. Biomaterial synthesis, nano sample preparation, cell culture and molecular biology experiments involved in the project can be completed in the biomaterial nanomedicine lab established by Dr. Zhang (about 150 ㎡ in total).


About NBM


Associate Professor   Doctoral supervisor

Department of Biomedical Engineering of SUSTech

Email: zhanglu@sustech.edu.cn

Pers. web: http://www.zhanglu_nbm_en.com

Dr. Zhang obtained his Ph.D. at Sun Yat-sen University in 2016 and became a post-doctoral fellow at University of California Davis from 2016 to 2021. As the first and corresponding author, Dr. Zhang has published 11 peer-reviewed papers in the famous international journals, such as Nat. Nanotechnol., Nano Lett., ACS Nano, Adv. Funct. Mater., etc. and has been authorized two international patents. He leads to successfully carry out three clinical translational projects of polyamine acid-based nanomedicines, one of which on targeted therapy of bladder cancer has been approved for phase I clinical trial in the United States.

Five Selected Publications

Human epidermal growth factor receptor 2 (HER2) is overexpressed in >20% of breast cancers. Dimerization of HER2 receptors leads to the activation of downstream signals enabling the proliferation...


To be clinically efficacious, nanotherapeutic drugs need to reach disease tissues reliably and cause limited side effects to normal organs and tissues. Here, we report a proof-of-concept study...


Sophisticated self-assembly may endow materials with a variety of unique functions that are highly desirable for therapeutic nanoplatform. Herein, we report the coassembly of two structurally...


Immune checkpoint blockade (ICB) therapy has revolutionized clinical oncology. However, the efficacy of ICB therapy is limited by the ineffective infiltration of T effector (Teff) cells to tumors...


Real-time tracking of the dynamics change of self-assembled nanostructures in physiological environments is crucial to improving their delivery efficiency and therapeutic effects. However, such...

Latest News



Dr. Zhang was invited to participate in the Tsinghua SIGS Health Engineering Forum and made a report    On May 13, Dr. Zhang was invited to participate in the Tsinghua SIGS Health Engineering Forum...



Dr. Zhang hosted the branch venue of 10th WACBE World Congress on Bioengineering (online) From April 22 to 23, 2022, the two-day 10th WACBE World Congress on Bioengineering was held by the World ...



Sponsored by the Chinese Society of Biomedical Engineering, and organized by Guangdong Academy of Medical Sciences, Southern University of Science and Technology, Shenzhen University of Technology...



On November 11th, Professor Zhang Lu was invited to attend the annual meeting of Molecular Imaging Branch of Guangdong Precision Medicine Application Association and the second South China...



 From October 1st to October 2nd, Professor Zhang Lu was invited by Professor Zhang Bin of Sun Yat-sen University to attend an academic seminar at Sun Yat-sen University, and negotiated project...